David A. Siegel Compass Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 86,400 shares of CMPX stock, worth $129,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
86,400
Previous 113,800
24.08%
Holding current value
$129,600
Previous $113,000
39.82%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CMPX
# of Institutions
79Shares Held
91.9MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$33.5 Million0.97% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.1MShares$16.7 Million0.04% of portfolio
-
Blackstone Inc New York, NY10MShares$15 Million0.09% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$9.92 Million0.0% of portfolio
-
Bio Impact Capital LLC Cambridge, MA5.64MShares$8.46 Million1.62% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $152M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...